Clean Cells, part of the Clean Biologics group, a leading biopharmaceutical quality control services provider specialising in biologics GMP testing, has announced the strategic acquisition of Karyologic Inc, a specialised karyotyping services company based in Durham, North Carolina, USA.
This strategic acquisition marks a key milestone in Clean Cells’ international growth: establishing an operational presence in the US.
Karyologic has established itself as a trusted provider of the cytogenetic testing services crucial for biologics development, as well as cell therapy products. This acquisition enables Clean Cells to immediately offer enhanced karyotype services to its North American clients, while setting the foundation to bring its comprehensive services offer closer to its US-based customers.
"This acquisition marks an exciting new chapter for Clean Cells as we strengthen our operational footprint in the US. Our ambition is clear: to support our clients' innovation in biologics with exceptional service capabilities both in Europe and North America," said Joseph Jammal, CEO of Clean Cells.
"Joining Clean Cells allows us to combine our expertise in cytogenetic analysis with their broad biologics service portfolio. This union ensures we deliver even greater value and reliability to our clients as part of a globally recognised organization," added Elizabeth Gonzalez, CEO of Karyologic.
The acquisition officially closed on 31 March 2025, setting in motion the immediate integration activities designed to leverage complementary strengths and enhance service delivery.